MRTX logo

Mirati Therapeutics (MRTX) Cash From Financing

Annual CFF

$166.94 M
-$338.28 M-66.96%

December 31, 2022

Summary

Performance

1-Year Change

-66.96%

3-Year Change

-50.61%

5-Year Change

+5.21%

15-Year Change

+5.21%

MRTX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$1.25 B
MRTX annual cash flow from financing activities is currently -86.65% below its historical high of $1.25 billion

3-Year Low

$166.94 M
MRTX annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
MRTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
MRTX next annual earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

Annual CFI

$225.80 M
MRTX annual cash flow from investing activities is $225.80 million

Annual CFO

-$570.57 M
MRTX annual cash flow from operations is -$570.57 million

Annual FCF

-$575.42 M
MRTX annual free cash flow is -$575.42 million

Annual CAPEX

$4.85 M
MRTX annual capital expenditures is $4.85 million

Quarterly CFF

$334.70 M
+$330.86 M+8609.34%

September 30, 2023

Summary

Performance

3-Month Change

+8609.34%

1-Year Change

+113.04%

3-Year Change

+2609.9%

5-Year Change

+15416.92%

MRTX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$889.89 M
MRTX quarterly cash flow from financing activities is currently -62.39% below its historical high of $889.89 million

3-Year Low

$1.39 M
MRTX quarterly cash flow from financing activities is currently >+9900.00% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

Quarterly CFI

-$62.19 M
MRTX quarterly cash flow from investing activities is -$62.19 million

Quarterly CFO

-$143.71 M
MRTX quarterly cash flow from operations is -$143.71 million

Quarterly FCF

-$143.75 M
MRTX quarterly free cash flow is -$143.75 million

Quarterly CAPEX

$36.00 K
MRTX quarterly capital expenditures is $36.00 thousand

TTM CFF

$346.19 M
+$177.59 M+105.34%

September 30, 2023

Summary

Performance

3-Month Change

+105.34%

1-Year Change

-45.93%

3-Year Change

-4.97%

5-Year Change

+2.41%

MRTX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$1.25 B
MRTX TTM cash flow from financing activities is currently -72.32% below its historical high of $1.25 billion

3-Year Low

$166.14 M
MRTX TTM cash flow from financing activities is currently +108.37% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
MRTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
MRTX next earnings announcement has not yet been scheduled

OtherMRTXcash flowmetrics:

TTM CFI

$207.79 M
MRTX TTM cash flow from investing activities is $207.79 million

TTM CFO

-$594.10 M
MRTX TTM cash flow from operations is -$594.10 million

TTM FCF

-$595.93 M
MRTX TTM free cash flow is -$595.93 million

TTM CAPEX

$1.84 M
MRTX TTM capital expenditures is $1.84 million

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

MRTX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-67.0%+113.0%-45.9%
3 y3 years-50.6%+2609.9%-5.0%
5 y5 years+5.2%+10000.0%+2.4%

MRTX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-67.0%at low-30.2%-99.6%-45.9%-52.0%
5 y5-year-86.7%at low-62.4%-99.6%-72.3%-52.0%
alltimeall time-86.7%-100.0%-62.4%-100.7%-72.3%-100.5%

Mirati Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2023
-
$334.70 M(+8609.3%)
$346.19 M(+105.3%)
Jun 2023
-
$3.84 M(+122.5%)
$168.59 M(+1.5%)
Mar 2023
-
$1.73 M(-70.8%)
$166.14 M(-0.5%)
Dec 2022
$166.94 M(-67.0%)
$5.92 M(-96.2%)
$166.94 M(-73.9%)
Sep 2022
-
$157.10 M(>+9900.0%)
$640.31 M(+30.3%)
Jun 2022
-
$1.39 M(-44.9%)
$491.43 M(-1.3%)
Mar 2022
-
$2.53 M(-99.5%)
$497.86 M(-1.5%)
Dec 2021
$505.22 M(-59.6%)
$479.28 M(+5722.2%)
$505.22 M(-44.8%)
Sep 2021
-
$8.23 M(+5.2%)
$915.83 M(-0.4%)
Jun 2021
-
$7.82 M(-20.9%)
$919.95 M(-0.2%)
Mar 2021
-
$9.88 M(-98.9%)
$921.40 M(-26.3%)
Dec 2020
$1.25 B(+270.0%)
$889.89 M(+7105.0%)
$1.25 B(+243.3%)
Sep 2020
-
$12.35 M(+33.2%)
$364.30 M(+3.2%)
Jun 2020
-
$9.27 M(-97.3%)
$353.02 M(-37.6%)
Mar 2020
-
$339.20 M(+9666.8%)
$565.63 M(+67.3%)
Dec 2019
$338.03 M(+140.0%)
$3.47 M(+224.0%)
$338.03 M(+0.9%)
Sep 2019
-
$1.07 M(-99.5%)
$335.02 M(-0.3%)
Jun 2019
-
$221.88 M(+98.8%)
$336.10 M(+36.3%)
Mar 2019
-
$111.60 M(>+9900.0%)
$246.56 M(+75.1%)
Dec 2018
$140.85 M(-11.2%)
$462.00 K(-78.6%)
$140.85 M(-38.8%)
Sep 2018
-
$2.16 M(-98.4%)
$230.03 M(+0.0%)
Jun 2018
-
$132.34 M(+2146.9%)
$230.02 M(+135.3%)
Mar 2018
-
$5.89 M(-93.4%)
$97.75 M(-38.4%)
Dec 2017
$158.68 M(+5883.3%)
$89.64 M(+4071.3%)
$158.68 M(+129.6%)
Sep 2017
-
$2.15 M(+2926.8%)
$69.10 M(+3.2%)
Jun 2017
-
$71.00 K(-99.9%)
$66.95 M(-0.3%)
Mar 2017
-
$66.82 M(>+9900.0%)
$67.14 M(+2431.7%)
Dec 2016
$2.65 M(-98.2%)
$60.00 K(>+9900.0%)
$2.65 M(-10.0%)
Sep 2016
-
$0.00(-100.0%)
$2.95 M(-97.0%)
Jun 2016
-
$266.00 K(-88.6%)
$98.02 M(-0.1%)
Mar 2016
-
$2.33 M(+555.2%)
$98.09 M(-32.1%)
Dec 2015
$144.37 M(>+9900.0%)
$355.00 K(-99.6%)
$144.37 M(+0.0%)
Sep 2015
-
$95.07 M(>+9900.0%)
$144.36 M(+192.3%)
Jun 2015
-
$335.00 K(-99.3%)
$49.39 M(+0.3%)
Mar 2015
-
$48.61 M(>+9900.0%)
$49.23 M(+5450.3%)
Dec 2014
$887.00 K
$351.00 K(+251.0%)
$887.00 K(-98.4%)
Sep 2014
-
$100.00 K(-42.5%)
$55.27 M(+0.1%)
Jun 2014
-
$174.00 K(-33.6%)
$55.19 M(+0.3%)
DateAnnualQuarterlyTTM
Mar 2014
-
$262.00 K(-99.5%)
$55.02 M(+0.5%)
Dec 2013
$54.76 M(+120.7%)
$54.73 M(>+9900.0%)
$54.76 M(+120.3%)
Sep 2013
-
$22.00 K(>+9900.0%)
$24.85 M(+0.1%)
Jun 2013
-
$0.00(0.0%)
$24.83 M(+0.1%)
Mar 2013
-
$0.00(-100.0%)
$24.82 M(+0.0%)
Dec 2012
$24.81 M(-22.1%)
$24.83 M(>+9900.0%)
$24.81 M(+5018.2%)
Sep 2012
-
$0.00(-100.0%)
$484.80 K(-127.9%)
Jun 2012
-
-$13.00 K(+333.3%)
-$1.74 M(-105.6%)
Mar 2012
-
-$3000.00(-100.6%)
$31.05 M(-2.5%)
Dec 2011
$31.84 M(+414.4%)
$500.80 K(-122.6%)
$31.84 M(+1.2%)
Sep 2011
-
-$2.22 M(-106.8%)
$31.45 M(-6.9%)
Jun 2011
-
$32.77 M(+4063.3%)
$33.78 M(+384.3%)
Mar 2011
-
$787.10 K(+578.0%)
$6.98 M(+12.7%)
Dec 2010
$6.19 M(+380.0%)
$116.10 K(+5.1%)
$6.19 M(-15.9%)
Sep 2010
-
$110.50 K(-98.1%)
$7.36 M(+1.5%)
Jun 2010
-
$5.96 M(>+9900.0%)
$7.25 M(+462.5%)
Mar 2010
-
$0.00(-100.0%)
$1.29 M(0.0%)
Dec 2009
$1.29 M(>+9900.0%)
$1.29 M(>+9900.0%)
$1.29 M(>+9900.0%)
Sep 2009
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2009
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2008
$0.00(-100.0%)
$0.00(0.0%)
$0.00(-100.0%)
Sep 2008
-
$0.00(0.0%)
$46.80 K(-96.5%)
Jun 2008
-
$0.00(0.0%)
$1.32 M(-51.1%)
Mar 2008
-
$0.00(-100.0%)
$2.71 M(-85.7%)
Dec 2007
$18.97 M(-17.5%)
$46.80 K(-96.3%)
$18.97 M(+6.0%)
Sep 2007
-
$1.28 M(-7.8%)
$17.90 M(+8.0%)
Jun 2007
-
$1.38 M(-91.5%)
$16.58 M(-53.1%)
Mar 2007
-
$16.27 M(-1687.3%)
$35.35 M(+53.7%)
Dec 2006
$23.01 M(<-9900.0%)
-$1.02 M(+1974.5%)
$23.01 M(-4.2%)
Sep 2006
-
-$49.40 K(-100.2%)
$24.03 M(-0.2%)
Jun 2006
-
$20.16 M(+414.1%)
$24.07 M(+514.7%)
Mar 2006
-
$3.92 M(<-9900.0%)
$3.92 M(<-9900.0%)
Dec 2005
-$3600.00(-100.0%)
-$4300.00(+2.4%)
-$3600.00(-614.3%)
Sep 2005
-
-$4200.00(-213.5%)
$700.00(-85.7%)
Jun 2005
-
$3700.00(+208.3%)
$4900.00(+308.3%)
Mar 2005
-
$1200.00
$1200.00
Dec 2004
$16.84 M(+1124.3%)
-
-
Dec 2003
$1.38 M
-
-

FAQ

  • What is Mirati Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Mirati Therapeutics?
  • What is Mirati Therapeutics annual CFF year-on-year change?
  • What is Mirati Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Mirati Therapeutics?
  • What is Mirati Therapeutics quarterly CFF year-on-year change?
  • What is Mirati Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Mirati Therapeutics?
  • What is Mirati Therapeutics TTM CFF year-on-year change?

What is Mirati Therapeutics annual cash flow from financing activities?

The current annual CFF of MRTX is $166.94 M

What is the all time high annual CFF for Mirati Therapeutics?

Mirati Therapeutics all-time high annual cash flow from financing activities is $1.25 B

What is Mirati Therapeutics annual CFF year-on-year change?

Over the past year, MRTX annual cash flow from financing activities has changed by -$338.28 M (-66.96%)

What is Mirati Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of MRTX is $334.70 M

What is the all time high quarterly CFF for Mirati Therapeutics?

Mirati Therapeutics all-time high quarterly cash flow from financing activities is $889.89 M

What is Mirati Therapeutics quarterly CFF year-on-year change?

Over the past year, MRTX quarterly cash flow from financing activities has changed by +$177.59 M (+113.04%)

What is Mirati Therapeutics TTM cash flow from financing activities?

The current TTM CFF of MRTX is $346.19 M

What is the all time high TTM CFF for Mirati Therapeutics?

Mirati Therapeutics all-time high TTM cash flow from financing activities is $1.25 B

What is Mirati Therapeutics TTM CFF year-on-year change?

Over the past year, MRTX TTM cash flow from financing activities has changed by -$294.12 M (-45.93%)